Meeting
2015 ASCO Annual Meeting
Evaluation of the value of serum glycomics (GlycoCirrhoTest) for risk prediction of hepatocellular carcinoma in compensated cirrhosis.
Authors
Xavier Verhelst
Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent, Belgium
Xavier Verhelst , Dieter Vanderschaeghe , Laurent Castera , Anja Geerts , Nathalie Goutté , Claire Francoz , Francois Durand , Nico Callewaert , Hans Van Vlieberghe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4079)
DOI
10.1200/jco.2015.33.15_suppl.4079
Abstract #
4079
Poster Bd #
189
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Interim analysis of hepatocellular carcinoma (HCC) screening and survival in 4,087 veterans diagnosed with HCC from 2008 to 2010.
First Author: David Edward Kaplan
Poster
2012 Gastrointestinal Cancers Symposium
Treating chronic hepatitis in Asian and Pacific island populations: A comparison of program costs according to current treatment guidelines.
First Author: Monica Cristina Robotin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line therapies in a Latino-rich cohort of US patients (pts) with hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis.
First Author: Moses Andrew Alfaro
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A single-center, real-world experience of atezolizumab plus bevacizumab as first-line therapy in patients with unresectable hepatocellular carcinoma, including patients with advanced cirrhosis.
First Author: Jay Parekh